Nuvation Bio (NUVB) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Nuvation Bio published the results on November 4, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Nuvation Bio's release gives no revenue or earnings outlook.
• Nuvation Bio began distributing IBTROZI in the U.S. in June 2025, so Q3 2025 was its first full quarter of product sales.

Source: Nuvation Bio Q3 2026 results, November 4, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Nuvation Bio splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Nuvation Bio's Product revenue, net (IBTROZI) revenue was $27.5 million in Q3 2026, up 256% from $7.7 million in Q3 2025, 61% of total revenue.
• Nuvation Bio's Collaboration and license agreements revenue revenue was $17.5 million in Q3 2026, up 224% from $5.4 million in Q3 2025, 39% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Total revenues and diluted net income (loss) per share, each as first reported in that quarter's release. Q1 2026 revenue includes license revenue from the upfront payment under Nuvation Bio's agreement with Eisai.

We do not hold a confirmed date for Nuvation Bio's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 4, 2026

Nuvation Bio's revenue comes from one drug, IBTROZI (taletrectinib), a ROS1 inhibitor for advanced ROS1-positive non-small cell lung cancer. U.S. net product revenue from IBTROZI was $27.5 million in Q3 2026, up 18% from the previous quarter and up from $7.7 million a year earlier, and collaboration and license revenue from partners added $17.5 million, for total revenues of $45.0 million. (Nuvation Bio Q3 2026 release, Nov 4, 2026)

Nuvation Bio counted about 160 new IBTROZI patient starts in Q3, level with the prior quarter while new starts across the whole ROS1-positive TKI market fell about 15%, based on IQVIA claims data. 65% of those starts were TKI-naive patients. In September 2026 the FDA approved an updated label showing a 49.7-month median duration of response in TKI-naive patients in the TRUST-I study. (Nuvation Bio Q3 2026 release, Nov 4, 2026)

Collaboration revenue rose to $17.5 million from $5.4 million because of a $7.6 million increase in product supply revenue, a $5.0 million sales milestone from Innovent and $2.4 million more royalty revenue, partly offset by $2.9 million less research and development service revenue from Innovent and Nippon Kayaku. Taletrectinib was added to China's National Reimbursement Drug List from January 1, 2026, and royalties from China and Japan were $2.7 million in the quarter. (Nuvation Bio Q3 2026 release, Nov 4, 2026)

By customer location, $27.5 million of Q3 2026 revenue was from the United States, $15.6 million from China and $1.9 million from Japan. Four customers each made up more than 10% of gross revenue in the quarter, at 28%, 21%, 19% and 12%. (Nuvation Bio Form 10-Q, Q3 2026, Nov 4, 2026)

Nuvation Bio lost $41.9 million in Q3 2026, or $0.12 per share, against $55.8 million, or $0.16, a year earlier. Higher revenue narrowed the operating loss to $42.2 million from $56.4 million even though research and development rose to $32.7 million from $28.8 million, mainly on clinical trial costs, and SG&A rose to $42.6 million from $37.4 million. (Nuvation Bio Q3 2026 release, Nov 4, 2026)

Cost of collaboration and license revenue was $9.8 million and cost of product sales $2.1 million. Interest income of $6.2 million roughly offset $6.1 million of interest expense. Nuvation Bio has sold $287.5 million of 0.75% convertible senior notes due 2032, including $37.5 million when underwriters exercised their option in July 2026, and carries a $150.0 million synthetic royalty financing with Sagard. It reports no adjusted EPS. (Nuvation Bio Q3 2026 release, Nov 4, 2026; Nuvation Bio Form 10-Q, Q3 2026, Nov 4, 2026)

Weighted-average shares, basic and diluted, were 351,861 thousand against 342,393 thousand a year earlier. Nine-month results included a $9.5 million loss on debt extinguishment and a $2.9 million gain on the warrant liability. (Nuvation Bio Q3 2026 release, Nov 4, 2026; Nuvation Bio Form 10-Q, Q3 2026, Nov 4, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Nuvation Bio does not give a revenue or earnings outlook in its release. The milestones it lists are clinical and regulatory: the Phase 3 SIGMA study of safusidenib in IDH1-mutant glioma, which received FDA Fast Track Designation in August 2026 and is adding sites in six European countries, a Phase 3 G307 study outside the U.S., a Phase 2 G209 study, and updates on its drug-drug conjugate platform by year-end 2026. (Nuvation Bio Q3 2026 release, Nov 4, 2026)

A consensus figure is the average of the models published by the analysts who cover Nuvation Bio, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Nuvation Bio's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning NUVB is on is NUVB a buy or a sell?, what analysts expect next is on the NUVB forecast, and what the company does is on the Nuvation Bio (NUVB) stock page.

Every number on this page can be traced to a document Nuvation Bio published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.